Genmab A/S (NASDAQ:GMAB) Upgraded by BNP Paribas to Hold Rating

BNP Paribas upgraded shares of Genmab A/S (NASDAQ:GMAB) from a strong sell rating to a hold rating in a research note published on Tuesday morning,Zacks.com reports.

GMAB has been the subject of a number of other reports. HC Wainwright reissued a “buy” rating and set a $50.00 target price on shares of Genmab A/S in a research note on Thursday, January 23rd. BMO Capital Markets reissued an “outperform” rating and issued a $48.00 price objective (up from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. Sanford C. Bernstein raised shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, December 20th. Finally, Leerink Partners raised Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price objective on the stock in a research note on Thursday. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $42.17.

Genmab A/S Stock Up 4.2 %

GMAB stock opened at $19.69 on Tuesday. Genmab A/S has a twelve month low of $18.64 and a twelve month high of $31.88. The stock has a market capitalization of $13.03 billion, a price-to-earnings ratio of 19.12, a price-to-earnings-growth ratio of 0.54 and a beta of 0.96. The firm’s fifty day simple moving average is $20.68 and its two-hundred day simple moving average is $23.21.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings data on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, topping analysts’ consensus estimates of $0.28 by $0.29. Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. As a group, equities research analysts expect that Genmab A/S will post 1.25 EPS for the current year.

Institutional Trading of Genmab A/S

Hedge funds and other institutional investors have recently bought and sold shares of the stock. EverSource Wealth Advisors LLC raised its position in shares of Genmab A/S by 295.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company’s stock worth $26,000 after acquiring an additional 939 shares in the last quarter. Lindbrook Capital LLC lifted its position in shares of Genmab A/S by 105.4% during the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company’s stock valued at $39,000 after buying an additional 950 shares during the last quarter. GAMMA Investing LLC boosted its holdings in shares of Genmab A/S by 96.6% in the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock valued at $45,000 after buying an additional 1,051 shares in the last quarter. Cromwell Holdings LLC boosted its holdings in shares of Genmab A/S by 656.8% in the 4th quarter. Cromwell Holdings LLC now owns 2,876 shares of the company’s stock valued at $60,000 after buying an additional 2,496 shares in the last quarter. Finally, R Squared Ltd purchased a new position in shares of Genmab A/S in the 4th quarter worth approximately $93,000. Institutional investors own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.